Data-Driven Decision Support in Obesity Management Commission: enabling more equitable and personalized obesity care

Paul W. Franks / nature - Nature Medicine, Published online: 12 May 2026; doi:10.1038/s41591-026-04363-0Announced in this Comment and in collaboration with Nature Medicine is the convening of the Data-Driven Decision Support in Obesity Management Commission, to promote adequate sc…

AI Summary: A phase 1/2 study of CRISPR‑Cas9 CD33‑deleted allogeneic hematopoietic cell transplantation followed by gemtuzumab ozogamicin maintenance reports encouraging early signals in AML. The gene‑editing approach aims to protect donor cells from CD33‑targeted therapy, potentially enabling safer post‑transplant maintenance and offering a novel strategy to marry cellular engineering with targeted antibody therapy.


CD33‑targeted transplant and post‑transplant maintenance

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily

3 months / medicalxpress


Safety and ethical scrutiny of gene editing and gene therapy

3 months / oncodaily


Scaling cell therapy: accreditation and expanding CAR indications


All Other Stories

3 months / esmo

3 months / nature

3 months / newscientist

3 months / oncodaily

3 months / oncodaily

3 months / medicalxpress

3 months / oncodaily

3 months / oncodaily

3 months / oncodaily


Back to Top / Sat, May 16, 2026, 5:21 pm / permalink 23912 / 24 stories in 3 months /




Related Stories


Enhertu (DESTINY‑Lung04) improves PFS in HER2‑mutant lung cancer / 6 days

Engineered bacteria show promise as tumor‑targeting therapy in preclinical studies / 5 wks

Daraxonrasib shows encouraging activity in NRAS-driven melanoma patients / 6 wks

CAR‑T depletes mutant calreticulin cells, offering myelofibrosis hope / 1 month

Rogaratinib shows activity in SDH‑deficient GIST phase 2 trial / 3 months

Decade-Long Persistence of CD19 CAR‑T Cells in B‑Cell Lymphomas / 14 days

Genetic clues explain tagraxofusp resistance in rare leukemia (BPDCN) / 7 wks

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Mergers and Acquisitions, Olfaction, Product Recall, Hearing Loss and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.